Breast Cancer

Hormonal Therapy for Metastatic Breast Cancer

May 23, 2016

To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) provides recommendations on the use of hormonal therapy for metastatic breast cancer. This guide for patients is based on the most recent recommendations.

About metastatic breast cancer

Metastatic breast cancer is cancer that has spread from the breast to another part of the body or has come back in another distant location. This area of spread is called a metastasis, or metastases if the cancer has spread to more than 1 area.

New Targeted Drug Slows Growth and Spread of Metastatic Breast Cancer

ASCO Annual Meeting
May 30, 2015

A large phase III study has found that a new targeted therapy, called palbociclib (Ibrance), delayed the growth and spread of advanced hormone receptor-positive breast cancer by roughly five months when combined with the standard hormonal therapy fulvestrant (Faslodex). This combination could become a new treatment option for women with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body.

Anastrazole Helps Reduce Breast Cancer Risk after DCIS for Postmenopausal Women

ASCO Annual Meeting
May 30, 2015

A large clinical trial suggests that anastrazole (Arimidex) may be a new option for preventing breast cancer after treatment for ductal carcinoma in situ (DCIS). DCIS is a non-invasive type of breast cancer. DCIS can usually be eliminated with a lumpectomy followed by radiation therapy. However, women with DCIS are at increased risk for developing invasive breast cancer in the same or opposite breast.


Subscribe to RSS - Breast Cancer